Home
·
Merck Group
·
Contact
·
DE
·
EN
·
Sitemap
·
Help
·
Search
Sitemap
Merck 2008 at a glance
Achievements of 2008
Development 1999-2008
Staying the course
Business sectors
Financial calendar
Letter from
Karl-Ludwig Kley
Corporate governance and Board
Corporate governance
Merck KGaA
Remuneration and ownership of shares
Report of the Supervisory Board
Executive Board
Dr. Karl-Ludwig Kley
Dr. Michael Becker
Dr. Bernd Reckmann
Elmar Schnee
Supervisory Board
Board of Partners of E. Merck KG
Merck shares
Share price development
Share data
Analysts’ estimates
Shareholder structure
Information on capital and shares
Management Report
Overall economic situation
Financial position and results of operations
Earnings development
Exceptional items
Financial result
Regions
Business sectors
Pharmaceuticals
Chemicals
Profit after tax
Dividend proposal
Free cash flow
Total assets
Capital spending
Value added
Responsibility
Employees
Community
FTSE4Good
Environment and safety
Corporate and Other
Risk report
Business-related risks
Financial risks
Rating
Legal risks
Human resource risks
Other risks
Report on expected developments
Subsequent events
Pharmaceuticals
Merck Serono
Business development
Regions
Therapeutic areas
Oncology
Neurodegenerative Diseases
Autoimmune and Inflammatory Diseases
Fertility
Endocrinology
CardioMetabolic Care
Research and development
Overview compounds
Cooperations
Oncology
Neurodegenerative Diseases
Fertility
Autoimmune and Inflammatory Diseases
Endocrinology
Consumer Health Care
Business development
Regions
Brands
Chemicals
Liquid Crystals
Business development
Research and development
Performance & Life Science Chemicals
Business development
Regions
Laboratory Business
Life Science Solutions
Pigments
Financial Statements
Income Statement
Balance Sheet
Segment Reporting
Business sectors
Regions
Cash Flow Statement
Free Cash Flow
Income and Expense
Changes in Net Equity
Notes
Acquisitions
Disposals/Discontinued operations
Accounting policies
Notes to the income statement
Sales
Royalty income
Cost of sales
Marketing and selling expenses
Administration expenses
Other operating income and expenses
Research and development
Amortization of intangible assets
Investment result
Exceptional items
Financial result
Income tax
Profit after tax from discontinued operations
Minority interest
Earnings per share
Notes to the balance sheet
Cash and cash equivalents
Marketable securities
Trade accounts receivable
Inventories
Other assets
Tax receivables
Assets/ liabilities held for sale
Intangible assets
Property, plant and equipment
Non-current financial assets
Financial liabilities
Trade accounts payable
Other liabilities
Tax liabilities
Provisions
Provisions for pensions
Net equity
Notes to the segment reporting
Notes to the cash flow statement
Net cash flows from operating activities
Net cash flows from investing activities
Net cash flows from financing activities
Cash and cash equivalents
Free cash flow
Other disclosures
Derivative financial instruments
Management of financial risks
Other disclosures on financial instruments
Contingent liabilities
Other financial obligations
Personnel expenses
Material costs
Auditors' fees
Corporate Governance
Companies opting for exemption
Related-party disclosures
Preparation and approval
Auditor's Report
SERVICES
Recommend page
Print page
Order online
Glossary
Downloads
CHART GENERATOR
Important key figures
Merck 2008 at a glance
Letter from
Karl-Ludwig Kley
Corporate governance
and Board
Merck shares
Management Report
Pharmaceuticals
Chemicals
Financial Statements
Notes
made by Nexxar - your next annual report online!, Vienna - Austria
